Free Trial

Retirement Planning Co of New England Inc. Purchases Shares of 2,766 Agilent Technologies, Inc. (NYSE:A)

Agilent Technologies logo with Medical background

Retirement Planning Co of New England Inc. acquired a new position in Agilent Technologies, Inc. (NYSE:A - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,766 shares of the medical research company's stock, valued at approximately $324,000.

Other hedge funds have also recently made changes to their positions in the company. Brighton Jones LLC boosted its stake in Agilent Technologies by 6.1% during the fourth quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company's stock worth $626,000 after acquiring an additional 270 shares in the last quarter. Commonwealth Equity Services LLC boosted its position in shares of Agilent Technologies by 9.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 43,862 shares of the medical research company's stock worth $5,892,000 after purchasing an additional 3,915 shares in the last quarter. Cibc World Markets Corp grew its stake in shares of Agilent Technologies by 14.5% in the 4th quarter. Cibc World Markets Corp now owns 45,340 shares of the medical research company's stock valued at $6,091,000 after buying an additional 5,735 shares during the period. Intech Investment Management LLC grew its stake in shares of Agilent Technologies by 19.2% in the 4th quarter. Intech Investment Management LLC now owns 1,643 shares of the medical research company's stock valued at $221,000 after buying an additional 265 shares during the period. Finally, Xponance Inc. increased its position in Agilent Technologies by 0.9% in the 4th quarter. Xponance Inc. now owns 42,381 shares of the medical research company's stock valued at $5,693,000 after buying an additional 396 shares in the last quarter.

Analyst Ratings Changes

Several research analysts have issued reports on the company. JPMorgan Chase & Co. cut their price target on Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating on the stock in a report on Thursday, May 29th. Wall Street Zen upgraded Agilent Technologies from a "hold" rating to a "buy" rating in a report on Saturday, June 28th. Barclays lifted their price target on shares of Agilent Technologies from $115.00 to $125.00 and gave the company an "equal weight" rating in a research report on Tuesday, June 24th. UBS Group lowered their price objective on shares of Agilent Technologies from $150.00 to $130.00 and set a "neutral" rating on the stock in a report on Thursday, May 29th. Finally, Evercore ISI raised their price objective on shares of Agilent Technologies from $125.00 to $130.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Agilent Technologies currently has a consensus rating of "Moderate Buy" and an average price target of $139.77.

View Our Latest Stock Analysis on A

Insider Buying and Selling at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 1,508 shares of the stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $117.44, for a total transaction of $177,099.52. Following the sale, the chief executive officer owned 37,448 shares of the company's stock, valued at approximately $4,397,893.12. This represents a 3.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Agilent Technologies Trading Up 2.6%

NYSE A opened at $116.42 on Friday. The business's fifty day moving average is $115.90 and its 200-day moving average is $122.30. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.09 and a quick ratio of 1.60. The stock has a market capitalization of $33.07 billion, a price-to-earnings ratio of 28.75, a PEG ratio of 3.44 and a beta of 1.23. Agilent Technologies, Inc. has a one year low of $96.43 and a one year high of $153.84.

Agilent Technologies (NYSE:A - Get Free Report) last released its earnings results on Wednesday, May 28th. The medical research company reported $1.31 earnings per share for the quarter, beating analysts' consensus estimates of $1.26 by $0.05. Agilent Technologies had a net margin of 17.59% and a return on equity of 25.92%. The firm had revenue of $1.67 billion for the quarter, compared to analysts' expectations of $1.63 billion. During the same period in the previous year, the company earned $1.22 earnings per share. The company's quarterly revenue was up 6.0% on a year-over-year basis. Equities research analysts predict that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 23rd. Stockholders of record on Tuesday, July 1st will be issued a $0.248 dividend. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date is Tuesday, July 1st. Agilent Technologies's payout ratio is currently 24.44%.

About Agilent Technologies

(Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Featured Articles

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Agilent Technologies Right Now?

Before you consider Agilent Technologies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.

While Agilent Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

3 Cheap Growth Stocks Set to Explode This Summer
3 Defense Stocks Under $10 With Massive Upside
3 Tech Stocks Insiders Are Buying: Speculative Plays for June

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines